Astellas acquires build-to-buy Mitobridge

Astellas Pharma Inc. (Tokyo:4503) exercised its exclusive option to acquire mitochondrial disorder company Mitobridge Inc. (Cambridge, Mass.) for $225 million

Read the full 208 word article

User Sign In